Simplex Trading’s NervGen Pharma NGEN Stock Holding History

Simplex Trading’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Buy	158,300 +158,100	+79,050%	+$491K	﹤0.01%	4127
2026 Q1	$754	Buy	+200	New	+$866	﹤0.01%	8662

Other funds holding NGEN

EAM

Empery Asset Management New York $86.5M AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Simplex Trading's NGEN Position: Q2 2026 in Review

Simplex Trading sold out of NervGen Pharma (NGEN) in Q2 2026, closing a stake of 27 shares — an estimated $84 sold.

Simplex Trading first reported a position in NGEN in Q1 2026 and held it in 1 quarter. The position peaked at $101 in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

Simplex Trading reported no remaining NervGen Pharma position as of Q2 2026 after selling out during the quarter.
Simplex Trading sold 27 NervGen Pharma shares in Q2 2026, an estimated $84.
Simplex Trading first reported a position in NervGen Pharma in Q1 2026 and held it in 1 quarter.
Simplex Trading's NervGen Pharma position peaked at $101 in Q1 2026.
62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.